In the chart on the right, the progressive improvements in ... on the SG&A line and to the extent that our partners are able ...
Third Quarter 2024 Results Key Financial Results Revenue: US$54.6m (up 37% from ...
A study on mice investigating therapeutic food for malnourished children uncovers diverse functions of a newly identified gut ...
From 2011 to 2022, there was an increase in autism spectrum disorder (ASD) diagnoses among children and adults.
Zacks.com on MSN2d
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue GrowthAcadia Pharmaceuticals ACAD reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS ...
Third Quarter Revenue was $509.0 million, a 6.5% increase over the prior year period Gross margin increased 8.4% to $159.7 million, compared to Q3 2023 Third Quarter Net loss was $42.8 million, compar ...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced that the U.S. Food and Drug ...
This said, the outcome from last night likely will impact which sectors do best. As we’ve noted repeatedly, Trump’s growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback